Please login to the form below

Not currently logged in
Email:
Password:

advanced breast cancer

This page shows the latest advanced breast cancer news and features for those working in and with pharma, biotech and healthcare.

Strong five-year survival data for Kisqali in breast cancer

Strong five-year survival data for Kisqali in breast cancer

Novartis’ Kisqali plus letrozole offers more than a year survival benefit for postmenopausal women with HR+/HER2 advanced breast cancer. ... evaluating Kisqali compared to palbociclib in patients with HR+/HER2- advanced breast cancer with aggressive

Latest news

More from news
Approximately 1 fully matching, plus 164 partially matching documents found.

Latest Intelligence

  • 20 for 2020 – Five pharma companies to watch 20 for 2020 – Five pharma companies to watch

    advanced or refractory HER2-positive metastatic breast cancer, DS-8201 was recently approved by the FDA with the brand name Enhertu for the treatment of adult patients with unresectable or metastatic ... HER2 positive breast cancer who have received two

  • Leading AstraZeneca’s return to growth in Europe Leading AstraZeneca’s return to growth in Europe

    The drug has so far gained approval for use in patients with germline BRCA1/2-mutated (gBRCAm), human epidermal growth factor receptor 2 (HER2)- negative locally advanced or metastatic breast cancer, ... That’s a measure of its heightened ambitions in

  • The handover: Pfizer reshapes itself for a new era The handover: Pfizer reshapes itself for a new era

    Innovative health revenue increased 4% to $8.47bn, lifted by sales of blood thinner Eliquis and breast cancer drug Ibrance outside the US, among others. ... In October the FDA also approved Talzenna (talazoparib), a new treatment of deleterious or

  • Deal Watch January 2018

    The incoming cash will be used by Immunomedics to fund its operations into 2020 including to progress development of sacituzumab govitecan in metastatic triple-negative breast cancer (TNBC), advanced urothelial cancer ... that is highly selective for HER2

  • Digital disruption Digital disruption

    Targeting advanced breast cancer the partners will combine real-world patient data and cognitive computing to ‘optimise cancer care and improve outcomes’. ... Next, they draw in the basic signalling pathways that can go wrong in cancer cells.

More from intelligence
Approximately 0 fully matching, plus 11 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 4 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
90TEN

90TEN is a global healthcare communications consultancy with a mission to make people healthier and happier through life-changing education and...

Latest intelligence

Understanding behaviour change: A Porterhouse Insights specialism
...
Robust Review: COVID19 Assessment
See how our client utilized Rapid Payer Response (RPR) to stay informed and gain continuous insights during the recent global pandemic (COVID19)...
Human behaviour - Sept 21
All change – how untangling human behaviour can encourage better health
Driving better patient outcomes through clear, achievable practical steps that are underpinned by transparent evidence...